NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $9.00 +0.40 (+4.65%) Closing price 11/6/2026 04:00 PM EasternExtended Trading$9.00 0.00 (-0.01%) As of 11/6/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Capricor Therapeutics Stock (NASDAQ:CAPR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$8.30▼$9.1150-Day Range$5.74▼$10.0152-Week Range$2.96▼$40.37Volume4.64 million shsAverage Volume3.18 million shsMarket Capitalization$523.26 millionP/E RatioN/ADividend YieldN/APrice Target$30.25Consensus RatingHold Company Overview Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials. Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners. The company is led by Linda Marbán, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCAPR MarketRank™: 2.39620322316 of 5 starsCapricor Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 523rd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingCapricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialCapricor Therapeutics has a consensus price target of $30.25, representing about 236.1% upside from its current price of $9.00.Amount of Analyst CoverageCapricor Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.19) per share.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted37.62% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 6.58.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 5.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.55 News SentimentCapricor Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Capricor Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 16 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -22% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.20% of the stock of Capricor Therapeutics is held by insiders.Percentage Held by Institutions21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAPR Stock News HeadlinesCAPR Stock Rises As Clinical Trial Investigators Write To FDA Urging Approval For DeramiocelNovember 3, 2026 | finance.yahoo.comCapricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10November 3, 2026 | markets.businessinsider.comThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional accounts such as 401(k)s, IRAs and TSPs depend on markets free of government manipulation and economic crisis. The free 2027 Wealth Protection Guide details an IRS loophole that lets you move retirement savings tax-free and penalty-free into a time-tested vehicle. Learn how retirees can weigh protection strategies ahead of a possible power shift in January.November 8 at 1:00 AM | American Hartford Gold (Ad)FDA decision watch: Regeneron and Roche’s autoimmune drugs, Capricor’s DMD therapy in spotlightNovember 2, 2026 | msn.comCAPR stock rallies into FDA decision month: Retail spots approval 'tea leaves' in Capricor's launch team hiringNovember 2, 2026 | msn.comCAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision NearsOctober 21, 2026 | msn.comCapricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - SlideshowOctober 13, 2026 | seekingalpha.comCapricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy TranscriptOctober 7, 2026 | seekingalpha.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $28.86 at the beginning of the year. Since then, CAPR shares have decreased by 68.8% and is now trading at $9.00. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) posted its earnings results on Thursday, August, 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.11. Read the conference call transcript. Who are Capricor Therapeutics' major shareholders? Capricor Therapeutics' top institutional shareholders include Oppenheimer & Co. Inc. (0.35%), Commonwealth Equity Services LLC (0.12%), Profund Advisors LLC (0.05%) and SBI Securities Co. Ltd. (0.05%). Insiders that own company stock include Shinyaku Co Ltd Nippon, Anthony Bergmann and Karimah Es Sabar. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU) and Vaxart (VXRT). Company Calendar Last Earnings8/13/2026Today11/08/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CAPR's financial health is in the Green zone, according to TradeSmith. CAPR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075Employees231Year Founded2005Price Target and Rating Average Price Target for Capricor Therapeutics$30.25 High Price Target$60.00 Low Price Target$2.00 Potential Upside/Downside+236.1%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.60% Return on Assets-43.97% Debt Debt-to-Equity RatioN/A Current Ratio7.35 Quick Ratio7.35 Sales & Book Value Annual Sales$22.27 million Price / Sales23.50 Cash FlowN/A Price / Cash FlowN/A Book Value$5.53 per share Price / Book1.63Miscellaneous Outstanding Shares58,140,000Free Float52,790,000Market Cap$523.26 million OptionableOptionable Beta0.80 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CAPR) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe IRS loophole Trump fought to preserve for retirees401(k) balances have reached record highs on a rising stock market and strong job growth. But traditional acco...American Hartford Gold | SponsoredA monthly income idea that does not require selling sharesA $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
